iBio Announces New Appointment to Board of Directors and New Addition to Executive Management Team

   iBio Announces New Appointment to Board of Directors and New Addition to
                          Executive Management Team

- Seymour Flug, former chairman of Diner's Club International, joins iBio
Board of Directors

- Andrea Corcoran, an experienced biotech executive, is added to iBio
executive management team

PR Newswire

NEWARK, Del., Dec. 21, 2012

NEWARK, Del., Dec. 21, 2012 /PRNewswire/ --iBio, Inc. (NYSE MKT: IBIO)
announced today the appointment of Seymour Flug to the iBio Board of Directors
and the addition of Andrea Corcoran, as Senior Vice President, Finance and
Strategy, a newly created position on the iBio leadership team. Mr. Flug most
recently was the former chairman, president and CEO of Diner's Club
International and a managing director at Citibank. Previously he served as a
Senior Vice President at Hess Oil Company. Ms. Corcoran joins iBio following
roles with increasing responsibility for corporate, financial and business
development strategy formation and operations at Idenix Pharmaceuticals, Inc.,
and Tolerx, Inc., each biopharmaceutical companies engaged in the discovery
and development new and innovative pharmaceutical products.

(Logo: http://photos.prnewswire.com/prnh/20120419/NY91086LOGO )

"Sy is a veteran executive with extensive experience in finance and deal
making," said iBio's Executive Chairman and Chief Executive Officer, Robert B.
Kay. "We expect that his wide-ranging background in the financial operations
of multi-national companies and business combinations will be of great benefit
to iBio as we continue to execute on our long-term strategic objectives."

On the addition of Ms. Corcoran to the executive management team, Robert
Erwin, President of iBio commented, "With the Company's recent progress and
current momentum, Andrea is arriving at a perfect to time to apply her
experience and proven capabilities to manage our growth and to optimize and
implement our business development and finance strategies. As we address the
opportunities ahead of us, we look forward to Andrea's contributions as an
integral member of our iBio team."

iBio also announced today that Jules Musing has resigned from iBio's Board of
Directors. "We are grateful for Jules' service on the Board," said Mr. Kay.

About iBio, Inc.

iBio develops and offers product applications of its iBioLaunch™ and
iBioModulator™ platforms, providing collaborators full support for turn-key
implementation of its technology for both proprietary and biosimilar
products. The iBioLaunch™ platform is a proprietary, transformative
technology for development and production of biologics using transient gene
expression in unmodified green plants. Advantages over other systems include:
success with proteins difficult or impossible to produce with other methods;
broadly applicable to biologics, including therapeutic proteins and vaccines;
production time measured in weeks instead of months or more. Additional
benefits include a practically unlimited surge capacity for remedial action
against bioterrorism and pandemic disease; product entry that is unconstrained
by traditional process patents, and significantly lower capital and operating
costs for comparable production. The iBioModulator™ platform is complementary
to the iBioLaunch™ platform and enables significantly improved vaccine
products with higher potency and greater duration of effect. The
iBioModulator™ platform can be used with most recombinant expression
technologies for vaccine development and production. Further information is
available at: www.ibioinc.com

Forward-Looking Statements

Statements included in this news release related to iBio, Inc. may constitute
forward-looking statements within the meaning of the Private Securities
Litigation Reform Act of 1995. Such forward-looking statements include those
regarding the expected benefit to be derived by iBio from Mr. Flug's
appointment on the Board of Directors and the anticipated contributions to be
made by Ms. Corcoran. These statements are subject to numerous factors, risks
and uncertainties that may cause actual events or results to differ materially
from the company's current expectations. Such risks and uncertainties may
include lack or insufficiency of available capital, intellectual property
protection issues, competitive factors, technological development, market
demand, and the Company's ability to obtain new contracts and accurately
estimate net revenues due to variability in size, scope and duration of
projects. Further information on potential risk factors that could affect the
Company's financial results can be found in the company's Reports filed with
the Securities and Exchange Commission.


Robert Erwin, President
iBio, Inc.


Douglas Beck, CFO
iBio, Inc.

SOURCE iBio, Inc.

Website: http://www.ibioinc.com
Press spacebar to pause and continue. Press esc to stop.